BeyondSpring, Inc.

Contributing Author

Recent Articles by BeyondSpring, Inc.

Dec-12	BeyondSpring Announces ESMO Asia Presentation on Plinabulin + Docetaxel Improving Survival in Large Phase 3 DUBLIN-3 Asian Subset for EGFR WT NSCLC Compared to Docetaxel, Strengthening the Case for a Global Registration Path BYSI GlobeNewswire
Dec-11	BeyondSpring Announces New Analyses of DUBLIN-3 Phase 3 Study Showing Survival Benefit of Plinabulin + Docetaxel in Post Anti-PD-(L)1 for Non-squamous EGFR WT NSCLC and a Reduction in Brain Metastasis Compared to Docetaxel at NACLC 2025 BYSI +7.92% GlobeNewswire
Nov-12	BeyondSpring Reports Third-Quarter 2025 Financial Results and Provides Corporate Update BYSI GlobeNewswire
Aug-13	BeyondSpring Reports Second-Quarter 2025 Financial Results and Provides Corporate Update: Accelerates Momentum with Promising Clinical Advances and Strategic Leadership Appointment BYSI GlobeNewswire
Jul-07	BeyondSpring Publishes Human Clinical Study in Med (Cell Press) Showing Plinabulin-Driven Dendritic Cell Maturation and Tumor Response After Prior Checkpoint Inhibitor Failure BYSI GlobeNewswire
Jun-03	BeyondSpring Presents Efficacy/Safety Data from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at 2025 ASCO Annual Meeting BYSI GlobeNewswire
May-28	BeyondSpring Announces Poster Presentation at 2025 ASCO Annual Meeting BYSI -5.68% GlobeNewswire
May-12	BeyondSpring Reports First-Quarter 2025 Financial Results and Provides Corporate Update BYSI GlobeNewswire